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Available online 11 February 2015AbstractAdoptive immunotherapy with T cells expressing a tumor-associated chimeric antigen receptor (CAR) provides a promising approach for
tumor therapy. We designed a clinical trial for multiple myeloma (MM) treatment with CAR-modified T cells recognizing CD138 (CART-138).
Five patients diagnosed with chemotherapy-refractory MM were enrolled into this trial, although one later advanced to plasma cell leukemia. By
intravenous infusions, these patients received CD3þ CART-138 cells in an escalating dose. No intolerable toxicity was observed during this
process. CART-138 cells were expanded to a level 1000 times higher than the initial engraftment level and were maintained in the peripheral
blood. In addition, increased CART-138 cells were also detected in the bone marrow. Four of the five patients had stable disease (SD) longer than
three months, and one patient with advanced plasma cell leukemia had a reduction of the myeloma cells in her peripheral blood (from 10.5% to
<3%). This study suggests that the treatment of CART-138 is safe, feasible, and tolerable and has potential antitumor activity in vivo, warranting
further research in MM treatment using CART-138.
Copyright © 2015, Shanghai Hengrun Biomedical Technology Research Institute. Publishing Services By Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Multiple myeloma (MM) is a fatal plasma cell neoplasm
affecting one to five per 100,000 individuals and constitutes
the second most common hematological malignancy [1].
Despite the application of auto/allo-hematopoietic stem cell
transplantation and the development of many new agents, such
as bortezomib, thalidomide, and lenalidomide, MM yet
currently remains incurable. The vast majority of MM patients
continue to suffer from relapses that are refractory to* Corresponding author. Tel./fax: þ86 10 66937463.
E-mail address: hanwdrsw@sina.com (W. Han).
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under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4chemotherapy based on immunomodulatory drugs (IMiD) and
proteasome inhibitors. The prognosis of such patients is very
poor, with a median overall survival of nine months and an
event-free survival of just five months [2]. Therefore, it is
urgent to find novel approaches for patients with
chemotherapy-resistant and advanced MM.
Ongoing studies with monoclonal antibodies could poten-
tially expand the armamentarium against myeloma and could
foster significant advances in the field. CD138 is highly
expressed on MM cells and is involved in their development
and/or proliferation [3], making CD138 an attractive thera-
peutic target [4e8]; however, the clinical benefit of anti-
CD138 therapy without immunoconjugate is very limited.
Clinical trial reports of labeled radioimmunotherapies, such as
iodine-131 anti-CD138 monoclonal antibody (mAb), have
suggested that CD138-directed cytotoxicity therapy may be ah Institute. Publishing Services By Elsevier B.V. This is an open access article
.0/).
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therapeutic strategy, especially for those patients refractory to
chemotherapy and with progressive MM [9].
The adoptive transfer of genetically engineered immune
effecter cells aims to rapidly establish T cell-mediated tumor
immunity. In this approach, the patient's own T cells are tar-
geted to tumor cells through a transgene-encoded antigen re-
ceptor consisting of either chains or a chimeric antigen
receptor (CAR) [10]. When expressed in T cells, CARs effi-
ciently redirect T cell specificity and cytotoxicity to cells
expressing the targeted antigen in an HLA-independent
manner. The CARs used in these experiments contained T
cell activation domains from molecules such as CD3z and a
variety of costimulatory domains, such as those from CD28
and 4-1BB. Recently accumulated clinical trial data have
demonstrated that genetically modified T cells with CAR
against CD19 or CD20 provide promising therapeutic strate-
gies for leukemias and lymphomas [11e14]. These reports
prompted us to initiate a pilot clinical trial on the treatment
with autologous T cells expressing an anti-CD138 chimeric
antigen receptor (CART138) for MM patients. This study is
registered at clinicaltrials.gov as #NCT01886976. To date, five
patients have been treated. Here, we report the feasibility and
clinical response of in vivo T cell treatment with CD138-
directed CAR in MM patients.
2. Materials and methods2.1. PatientFive patients were enrolled in this study (Table 1), the first
patient was enrolled into our clinical trial in July 2013 and the
last patient was enrolled in January 2014. The primary
endpoint was the time that the patients received complete
response or withdrew from the trial. All of these patients were
diagnosed as refractory and developed relapsed MM; one
patient was first diagnosed with plasma cell leukemia because
of the percentage of myeloma cells in the blood was above
10.5%. Before enrollment into our protocol, each patient had
received 5e18 standard chemotherapy, and one had been
treated with auto-PBSCT. We defined refractory as a 1-month
progression after the end of the most recent chemotherapy.
Before treatment, flow cytometry showed bone marrow aspi-
rates expressing a monoclonal phonotype and CD138 in all
five cases. Large numbers of cells with strong staining forTable 1
Baseline demographic and clinical patient characteristics.




1 57 Female MM (IgG-LAM, IIIB) 15 PD
2 62 Male MM (IgA-LAM, IIIA) 8 PD
3 55 Female MM (IgA-KAP, IIIA) 18 PD
4 68 Female MM (IgA-LAM, IIIB) 5 PD
5 48 Female MM (KAP, IIIA) 7 þ auto-PBSCT PD
SD is Stable disease. PD is Progressive disease.CD138 were detected in the bone marrow biopsy tissue by
immunohistochemistry before treatment. The clinical efficacy
was evaluated according to the international myeloma working
group (IMWG) (2009) [15]. Brifely, SD refers to stable dis-
ease that is described by providing the time to progression
estimates. PD is progressive disease in which patients with a
twenty-five percent increase of any of the response indicators
(M-protein, FLC, and bone marrow plasma cell percentages)
concurrently have new bone lesions or soft tissue plasmacy-
tomas or increase in the size of pre-existed tumor.2.2. Study designThe trial (Clinical Trials number, NCT01886976) was
designed to assess the safety and efficacy of infusing autolo-
gous CART138 T cells in patients with relapsed or refractory
multiple myeloma. The trial was approved by the institutional
review board at Chinese PLA General Hospital. No commer-
cial sponsor was involved in the study.2.3. Vector productionThe initial DNA sequence of the scFv domain targeting the
CD138 antigen was derived from NK-92-scFv (CD138)-z,
which had been identified to possess both ex vivo and in vivo
anti-myeloma effects when expressed on nature killer cells
[16]. According to the gene sequence in GenBank for the
fusion gene, anti-CD138-ScFV-CD8a-CD137-CD3x was
designed, synthesized, and inserted into the lentivirus pack-
aging plasmid vector pWPT (Fig. 1A). Then, the fusion gene,
together with plasmid psPAX2 and pMD2g transfected 293T
cells, were cultured with high glucose DMEM, including 10%
FBS, 100 U/ml penicillin and 100 mg/ml streptomycin. The
supernatant was collected, and the lentivirus was concentrated
in DMEM without FBS.2.4. Generation and expansion of CAR T cellsPB was collected in cell preparation tubes (BD Bio-
sciences), and PBMCs were isolated through Ficoll-Hypaque
density gradient centrifugation. Next, the PBMCs were
washed three times and cultured in a 25 cm2 flask that had
been coated with 5 mg/ml anti-human CD3 monoclonal anti-
body (Takara, Japan) at 4 C overnight for 2  106 cells/ml
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CP 2 SD (7)
CP 3 PD
VAD 3 SD (6)
Fig. 1. Generation and expansion of CART-138 cells (A) Schematic representation of the aCD138-8a-137-z chimeric T-cell receptor cDNA plasmid, not to scale.
(B) The median expansion (-fold) of control (NT; not transfected) and CART-138 cells generated from all patients after being cultured for approximately 11 days.
Means and SDs are shown for seven different T-cell lines. (C) Phenotypic analyses of PBMCs, NT and CART-138 cells. Phenotypic comparisons were performed in
samples from seven patients, and the results are expressed as the means ± SD. (D) Cytotoxic activity of control NT and CART138 cells obtained from three patients
(NPN 1, 3, and 5) using the HL-60 cell line (acute myeloid leukemia, CD138-), Cytotoxic activity was evaluated in a 6-h CFSE-staining assay, and the results are
shown as effector:target (E:T) ratios of 5:1, 10:1, 20:1, and 40:1. The data are represented as the means of triplicate values, and the error bars represent SEM. (E)
The verified percentage of CART-138 in the NT cells by FACS (left). The CART cells are shown in the optical microscope (middle), and the verified cells were
detected by fluorescence in situ hybridization (FISH) (right).
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nation human IFN-g (rhIL-2; Peprotech) and 1000 m/ml
recombination human IL-2 (rhIL-2; Peprotech) were added on
day 0 of culture. On day 2 of culture, the lentivirus plus 6 mg/
ml protamine sulfate salt from salmon were added into the
culture flask, and most of the cells adhered to flask. The cell
culturing supernatant was refreshed with IFN-g and IL-2 after
12 h. The second lentivirus transfection was performed on day
3 of culture. In addition, all of the cells were moved into a new
flask without precoated with GT-T551 medium supplementIL-2. Fresh GT-T551 medium and IL-2 were added every three
days. The cytokine-induced killer (CIK) cells were harvested
after approximately 11 days of culturing (Fig. 1B).2.5. Cytotoxicity assaysCytolytic activity of CART138 to HL-60 or HL-60/CD138
(HL-60 cells transfected to express CD138) was detected
using the standard 6-h carboxyfluorescein succinimidyl ester
(CSFE) cytotoxicity test [17]. Briefly, HL-60 or HL-60/CD138
31B. Guo et al. / Journal of Cellular Immunotherapy 2 (2016) 28e35was labeled with CFSE, and CART138 were subsequently
incubated with CFSE-labeled target cells for 6 h at the ratios
of 40:1, 20:1, 20:1, 5:1, and 1:1. The cells were then collected
and further stained with 7-aminoactinomycin D (7-AAD); 7-
AAD-positive cells were identified as dead cells.2.6. Real-time qPCRThe PBMCs collected serially after T-cell infusions were
isolated by Ficoll density gradient centrifugation, and genomic
DNA was extracted using a QIAamp DNA Blood Mini Kit
(Qiagen). The standard consisted of 10-fold serial dilutions of
purified scFvFc: plasmid DNA starting at 104 copies/UL, with
each sample containing 1 mg of preinfusion PBMC DNA to
control for background signals. The negative control was
preinfusion PBMC genomic DNA. A 153-bp (base pair)
fragment containing portions of the CD8a chain and adjacent
CD137 chain was amplified using forward primer 50-
GGTCCTTCTCCTGTCACTGGTT-30 and reverse primer 50-
TCTTCTTCTTCTGGAAATCGGCAG-30. The beta-actin
gene was used as an internal control. Quantitative real-time
PCR was performed in triplicate with 1 mg DNA in each re-
action, using SYBR qPCR Mix in a 7900HT Sequence
Detection System (all Applied Biosystems).2.7. StatisticsThe results are shown as the means ± standard error of the
mean (SEM). Data were plotted using GraphPad Prism version
5.0. Two way analysis of variance (ANOVA) was used to
determine the significance of the differences between the
means in all experiments. A P value <0.05 was considered to
be statistically significant.
3. Results3.1. Characterization and specific cytotoxicity in vitro of
patient-derived CART-138 cellsAfter 10- to 12-days of culture, the total numbers of
cultured cells reached to a 26- to 84-fold expansion and were
collected for infusions (Fig. 1B). Generally, the time needed to
achieve a clinical dose of CART-138 cells was 11 days. We
detected the subsets of cultured cells using FACS. As shown in
Fig. 1C, a mean of 97.08 ± 6.09% of the infused cells were
CD3þ cells and were principally composed by the CD8þTable 2
Acute adverse events after T cell infusion.
UPN Adverse events Grade Time of occurrence
1 Fever 3 1 h after infusion
2 None
3 Fever 3 4 h after infusion
4 Fever 3 2 h after infusion
5 Fever 3 40 min after infusion
The maximum grade experienced for the corresponding toxicity for a given patiensubset (average 71.89%), and a mean of 31.89% (range
11.73e41.33%) of the cells expressed CAR. We also defined
cytotoxicity of CART-138 cells against target cells. CART-138
cells and target cells were incubated at different E/T ratios. We
found that the cytolytic activity of CART-138 cells against
HL-60/CD138 was markedly increased compared with that
against HL-60 (Fig. 1D).3.2. Cell infusionsPB (fifty-ml) was collected to generating CIK cells with
the transduction of a chimeric antigen receptor recognizing
CD138. A split-dose cell infusion schedule was used to
address potential safety concerns related to the evaluation of
a previously untested CAR molecule. This protocol repre-
sents a standard phase one dose-escalation trial with 3e6
planned CD3þ T-cell doses, average of 0.756  107 CIK
cells per kilogram (the average percentage of verified CART-
138 cells in CD3þ cells was 32%) (Fig. 1E, Table 3).
Treatment was tolerated during the immediate process of
CAR cell infusion, including provisions for patients who
developed a transient infusion-associated chill and fever,
from which the patient automatically recovered overnight.
The general clinicopathological characteristics, pre-
conditioning regimens, and corresponding clinical responses
of patients prior to CART-138 infusions are summarized in
Tables 1 and 23.3. CART-138 cells in peripheral blood and bone
marrowWe measured the copy numbers of the CAR molecule to
determine the persistence of CART-138 cells in the pe-
ripheral blood at serial time points (Fig. 2A). A high copy
number of the CAR gene (>1000/gDNA) was persistently
maintained for at least four weeks in all patients. Among
these patients, UPN2 had the highest number of copies of
the CAR gene, which was continuously sustained for more
than five months. Based on Q-PCR assays, high copy
numbers of the CAR gene were also detected within one
week after infusion. The peak level of the cells was noted
approximately by day 10 after infusion in UPN1, 3, and 4;
interestingly, there was a delayed peak in UPN2 eight weeks
after infusion (Fig. 2B). However, a comparably delayed
level was detected in the bone marrow, which peaked six
weeks or later.Description Duration
With chills, the peak temperature was 39.2 C 30 min
With chills, nausea, the peak temperature was 39.5 C 90 min
With chills, nausea, the peak temperature was 39.5 C 50 min
With chills, nausea, the peak temperature was 39.6 C 2 h
t.
Table 3











1 72.5 39.29 28.49 0.44
2 124 41.33 51.25 0.73
3 272 33.39 90.82 1.51
4 132 34.18 45.12 0.66
5 189 11.73 22.17 0.44
Total 789.5 159.92 237.85 3.78
Mean 157.9 31.984 47.57 0.756
32 B. Guo et al. / Journal of Cellular Immunotherapy 2 (2016) 28e353.4. Toxicity of the CART-138 cellsNo intolerable toxicities were observed in this process.
Only fever due to grade 3 toxicities appeared (Table 2). TheFig. 2. Altered T and B cell counts in the PB and BM of patients after CART-
138 cell infusion. CART-138 sustained the in vivo expansion and persistence
of five patients in the PB (A) and BM (B) of CART138 cells. The CART-138
cells were assessed by quantitative real-time polymerase-chain-reaction
(qPCR) assay. Genomic DNA was isolated from samples of whole blood and
bone marrow aspirate at serial time points after CART-138 infusion.patients had infusion fevers after the second T-cell infusion;
the peak was 39.6 centigrade, which might have evolved into
the macrophage activation syndrome. Although there was no
direct evidence of tumor lysis syndrome, UPN1, UPN2, and
UPN4 showed the development of grade 2 nausea and vom-
iting on days 13eto18 with elevated CART-138 in the pe-
ripheral blood. In addition, UPN1 had a mildly elevated
aspartate aminotransferase (AST) level, indicating grade 1
adverse events. The causes were probably multifactorial but
could have included tumor lysis syndrome. For three months
after the infusion of CART-138 in all five patients, blood urea
nitrogen (BUN) and serum creatinine (Cr) fell within normal
ranges, there were no abnormalities in the serum calcium or
lactate dehydrogenase levels. Non-hematologic toxicity was
noted during the observation, and other adverse reactions did
not occur during treatment. (Adverse events were graded ac-
cording to the Common Terminology Criteria for Adverse
Events, version 3.0 (http://ctep.cancer.gov/)).3.5. Overall clinical responses to CART-138 therapyAll five patients were available to evaluate the objective
clinical responses after CART-138 therapy; four experienced
myeloma regression during this trial (Table 1). Within two
weeks from the beginning of the cell infusion, no obvious
disease progression was noted. The serum content of M pro-
teins continued to remain stable on day 14 after cell infusion,
and the stabilization spanned approximately three to four
weeks (UPN2, 3, 4, 5). However, a different tendency emerged
in the peripheral blood of UPN1, with the increasing levels of
CART-138 during two weeks after the cell infusions; myeloma
cells in the peripheral blood reduced rapidly (from 10.5% to
<3%) and were sustained for 12 weeks (Fig. 3A, B, C),
coinciding with the constitutional symptoms of tumor lysis
exhibited from day 16eto18. The patient's advanced disease
was successfully intervened upon, and she reentered a stable
status for 12 weeks. The conditions of the myeloma remained
stable in UPN3 and UPN5 for eight months without another
therapy among the two patients who submitted to follow up.
Myeloma of UPN2 showed a progression after five months of
infusion, and the IgG levels increased in the UPN4 after one
month of infusion, such that other palliative care measures
were administered.
4. Discussion
We studied five patients with advanced, progressive mul-
tiple myeloma on a clinical trial of chemotherapy followed by
an infusion of CART-138 cells. This approach demonstrated
that autologous PBMCs from MM patients could be reliably
modified to express a CD138-specific transgene-encoded an-
tigen, expanded in vitro, and reinfused with minimal toxicity.
Moreover, the advanced disease was induced to reenter into a
stable state after CART-138 infusions.
The treatment regimen used in this study is generally safe
and well tolerated. The process of generating therapeutic
numbers of CART-138 cells by limiting their dilutions proved
Fig. 3. Clinical responses after CART-138 cell infusions. (A) The results of the flow-cytometric analysis of the peripheral blood in UPN1 were stained with antibodies
CD138 to detect myeloma cells. The evaluation of CD138 positive cells was 10.5% on day 5 before the first infusion (left), and themyeloma cells decreased to 2.03% on
day 16 (right). (B)A bonemarrow smear ofUPN1was obtained five days before theCART-138 cell infusion and on days 13, 48, and 86 after theCART-138 cell infusion.
The baseline specimen shows hypercellular bone marrow (37.2%) with myeloma cells, which had increased to 67.6% by day 13. The specimen obtained on day 31
showed residual plasma cell aggregates (29.5%),whichwere reducedmore significantly than ever before. The evaluationofmyeloma in theBMwasmaintained at 32.5%
by12weeks after the infusion. (C) The detection of themyeloma cells ofUPN1 in a bonemarrow smear by FACSwas performed on day-5, 13, 48, and 86 after theCART-
138 cell infusion. The expressions of CD138-positive cells, respectively, were 50.45%, 60.38%, 58.49% and 46.76%.
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with a toxicity of only one or two grades in all five patients.
No evidence of obvious tumor lysis syndrome or an inflam-
matory storm was found under normal levels of serum calcium
or lactate dehydrogenase. The development of tumor lysis
syndrome after cellular immunotherapy has not been reported
previously [18]. CART cells are capable of generating exten-
sive cytotoxicity in vivo caused by cytokine production, which
was positively correlated with the degree of the tumor burden
and the infusion dose [19]. Therefore, an adverse reaction
could be provoked by administering CART cells to patients
with small disease burdens. Another possible means of
reducing acute toxicities after CART cell infusions is to ad-
ministrate multiple, smaller doses of CAR-transduced T cells
rather than one large dose [20]. The burden of myeloma in this
patient was not large; the cell proliferation of MM itself was
slow; and the process of infusion was divided into six doses,
none of which were sufficient to cause extensive damage.
The research for therapeutic choices of relapsed and re-
fractory MM is still ongoing because there is hardly any
conclusive data outlining the most appropriate way of treat-
ments for these in previous literature. The adoptive transfer of
genetically engineered immune effector cells to rapidly
establish T cell-mediated tumor immunity is the available
choice [21]. In this approach, the patient's own T cells are
targeted to tumor cells through a transgene-encoded Ag re-
ceptor consisting of a CAR, which is composed of an extra-
cellular Ag recognition domain, most commonly a single
chain fragment variable derived from a mAb that has been
fused to a transmembrane domain, and a cytoplasmic signalingdomain, most commonly including that of the CD3 chain
[10,21e23]. When expressed in T cells, CARs efficiently
redirect T-cell specificity and cytotoxicity toward cells
expressing the targeted Ag in HLA-independent manner
[24,25]. Previous research has shown that genetically modified
NK-92 cells expressing the CAR anti-CD138 were identified
to induce an intensified anti-myeloma immunoresponse and to
reinforce the lysis and apoptosis of myeloma cells in cell lines
and mice [16]. One study reported treating four patients of
progressive MM with iodine-131-labeled anti-CD138 mono-
clonal antibody (mAb). One patient of the four received partial
response, the other three patients did not achieve response,
their M-protein stayed in the peak. Moreover, one patient
suffered from 3/4-grade hematological toxicity for 39 days
after the treatment [9]. Efficacy was noted in this study,
although long-term outcomes should be followed up sepa-
rately. There were clinical responses in our research showing
that the advanced MM patients were returned to stable con-
ditions after CART-138 infusions. In one patient (UPN 1),
10.5% of CD138þ myeloma cells were observed in peripheral
blood before treatment with our protocol. After treatment,
when the patient was in remission, the level tended to be
1e3%. Detailed cell surface marker analysis was performed to
assess the phenotype of the expanded cells. The data indicate
that CART-138 cells can specifically recognize and kill un-
manipulated, autologous MM cells in vivo.
To act on and within the tumor, genetically modified T
cells must home to the site of the malignancy [10]. The
trafficking of modified T cells was detectable by qPCR in
the bone marrow 24eto48 h after the final infusion among
34 B. Guo et al. / Journal of Cellular Immunotherapy 2 (2016) 28e35the patients with lymphoma treated by CD20-specific
adoptive immunotherapy [11,26]. The CART-19 cells were
observed at high level within five weeks after therapy in the
BM of the patients with ALL and CLL [27]. In our study, a
high expansion of CART-138 could be detected after eight
weeks, and the cells were able to enter into the BM at a high
copy number. In UPN1, the expansion of CART-138 cells in
the BM increased persistently, although only until seven
weeks after the infusions. Therefore, the reduction of
myeloma in BM was not detected at the beginning of the
infusions, and even the proportion of plasma cells was
increased. Although there was no obvious decrease in the
plasma cell ratio of serial BM aspirates, cytoplasmic
swelling and membrane budding of these cells, but not of
other cell lineages, could be wildly observed in all patients
receiving CART-138 therapy, possibly implying the exis-
tence of a CART-138 triggered immune attack on
CD138 þ cells. For patients with the SD response, these
morphological changes, possibly induced by immune attack,
appeared to be more consistent and wild. There are many
possible explanations for the limited therapeutic antitumor
activity observed in this trial. First, the high IgG level in
blood of patients could have increased the blood viscosity,
thereby affecting the CART cells. Second, an ineffective
localization of the T cells to the tumor sites and inadequate
transgene-encoded antigen surface expression could also
affect the response of tumor cells to treatment. Third, the
cytokine microenvironment in tumors may affect the func-
tion of CART [28,29].
In summary, adoptive immunotherapy with CART-138 is a
safe, feasible, and well-tolerated treatment for the MM pa-
tients, and may constitute a promising strategy for the relapsed
or refractory MM. The present results are encouraging but also
identify areas for improvement to be addressed in future
CART-138 therapy trials for MM.
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